The power of ultra-genetics, that is the vision behind Amylon Therapeutics. Diseases that are long forgotten, that are ignored or deemed uninteresting commercially – they all potentially contain incredible power and the key to solving global therapeutic challenges. The exponential growth in population and life-expectancy confront us with diseases that reach epidemic proportions at an unprecedented pace. Alzheimer’s disease, elderly blindness, stroke and many more have become unbearable burdens on society and eluded therapeutic intervention.
Targeting these disorders face challenges beyond those at a therapeutic level. Due to their sheer size and global patient distribution, clinical development has become a financial and logistical challenge that only a handful in this world can take on. But what if we could find a way to bypass these challenges? To provide an achievable alternative that alters the very basis of this system? At Amylon we believe we can.
With our ultra-genetic approach we focus on rare genetic subtypes on global disorders, in which pathological mutations cause accelerated subtypes of otherwise sporadic disorders. Focussing on these disorders allows us to bypass the challenges of large clinical trials and the uncertainty of finding the right patients and intervening at the right time.
Thomas de Vlaam is a science entrepreneur who invented Amylon's lead program AT-010. He developed the program at ProQR Therapeutics as their therapeutic area leader for CNS indications. Thomas holds an International Bachelor's degree of Medicine and Global Health from the University of Groningen.